更新于：2024-12-07
Hydrocortisone Sodium Succinate
氢化可的松琥珀酸钠
更新于：2024-12-07
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H34NaO8 |
InChIKeyLGKJVUKNTHOZJH-CODXZCKSSA-N |
CAS号125-04-2 |
关联
31
项与 氢化可的松琥珀酸钠 相关的临床试验A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
An Open-label, Single-arm, Single-center Study Evaluating the Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
100 项与 氢化可的松琥珀酸钠 相关的临床结果
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的转化医学
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的专利（医药）
登录后查看更多信息
747
项与 氢化可的松琥珀酸钠 相关的文献（医药）2024-10-10Cureus Journal of Medical Science
Delayed Emergence of Isolated Secondary Adrenal Insufficiency: A Case Report
Article
作者: Ovalles Lacruz, Alexa ; Mesa, Natalie ; Blanco Guertin, Angela ; Vassil, Steven T ; Sharma, Deepa
Secondary adrenal insufficiency (SAI) is a rare condition caused by adrenocorticotropic hormone (ACTH) deficiency, which disrupts ACTH secretion by the pituitary gland and can lead to chronic hyponatremia. However, idiopathic delayed onset of isolated adrenal insufficiency without triggering factors is an unusual finding and poses a challenging diagnosis. We present the case of an 80-year-old woman with hypothyroidism, hypertension, previous tobacco use, and squamous cell carcinoma of the ankle who presented with weakness and fatigue. Blood work showed hyponatremia (126 mmol/L), nonfasting blood glucose of 139 mg/dL, and elevated erythrocyte sedimentation rate (ESR, 83 mm/hr). Initial treatment included urea administration and water restriction. Initial imagining included a CT of the chest which revealed mediastinal lymphadenopathy, leading to suspicion of the syndrome of inappropriate antidiuretic hormone (SIADH) from malignancy. Despite increasing urea and adding NaHCO3, sodium levels dropped further. Tolvaptan was administered but showed no improvement. Endocrinology recommended hydrocortisone sodium succinate (Solu-Cortef) leading to sodium normalization and symptom resolution. A full pituitary workup revealed low dehydroepiandrosterone sulfate (DHEA-S), and abdominal CT showed atrophic adrenal glands. MRI of the sella turcica was normal with no evidence of a mass. The patient was discharged on an oral course of Solu-Cortef with stable sodium levels (139 mEq/L). This is among the first reported cases of unprovoked isolated adrenal insufficiency with abnormal cortisol, ACTH, DHEA-S levels, and normal renin and aldosterone levels. Diagnosis is often delayed due to nonspecific symptoms. Once identified, corticosteroid replacement therapy is the gold standard for management.
2024-09-01STEROIDS
Biotransformation of hydrocortisone succinate with whole cell cultures of Monascus purpureus and Cunninghamella echinulata
Article
作者: Aziz, Zainab ; Rashid Khan, Afsana ; Sheema ; Iqbal, Amir ; Rahman Khan, Abdur ; Zafar, Salman
Hydrocortisone succinate (1) is a synthetic anti-inflammatory drug and key intermediate in the synthesis of other steroidal drugs. This work is based on the fungal biotransformation of 1, using Monascus purpureus and Cunninghamella echinulata strains. Comopound 1 was transformed into four metabolites, identified as hydrocortisone (2), 11β-hydroxyandrost-4-en-3,17-dione (3), Δ1-cortienic acid (4), and hydrocortisone-17-succinate (5), obtained through side chain cleavage, hydrolysis, dehydrogenation, and oxidation reactions. These compounds have previously been synthesized either chemically or enzymatically from different precursors. Though this is not the first report on the biotransformation of 1, but it obviously is a first, where the biotransformed products of compound 1 have been characterized structurally with the help of modern spectroscopic techniques. It is noteworthy that these products have already shown biological potential, however a more thorough investigation of the anti-inflammatory properties of these metabolites would be of high value. These results not only emphasize upon the immense potential of biotransformation in catalysis of reactions, otherwise not-achievable chemically, but also holds promise for the development of novel anti-inflammatory compounds.
2023-08-01Annales d'endocrinologie
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Review
作者: Tabarin, Antoine ; Dreves, Bleuenn ; Reznik, Yves
Congenital adrenal hyperplasia (CAH) is a genetic disease caused by an enzyme deficiency interrupting adrenal steroidogenesis. It most frequently involves 21-hydroxylase, which induces adrenal insufficiency with hyperandrogenism. Restoring hormonal balance is difficult with glucocorticoids, which are the gold-standard treatment. Strict normalization of conventional biomarkers (17-hydroxyprogesterone and delta-4 androstenedione) is often obtained at the cost of iatrogenic hypercortisolism. Optimizing the management of these patients first involves using more specific biomarkers of adrenal steroidogenesis in difficult situations, and secondly using therapeutics targeting the induced hypothalamic-pituitary-adrenal axis disorder. 11-oxygenated androgens are candidates for biochemical monitoring of Congenital adrenal hyperplasia (CAH), in particular 11-ketotestosterone. Numerous new therapeutic agents are currently being explored, the prime goal being to reduce glucocorticoid exposure, as no strategy can fully replace it at present. They can be divided into 3 categories. The first includes "more physiological" hydrocortisone administration (modified-release hydrocortisone and continuous subcutaneous infusion of hydrocortisone hemisuccinate); the second includes corticotropin releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) receptor antagonists and anti-ACTH antibodies; and the third includes steroidogenesis inhibitors. Finally, experiments on gene and cell therapies suggest the possibility of lasting remission or even cure in the future.
100 项与 氢化可的松琥珀酸钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 1968-04-23 | |
| 创伤性休克 | 日本 | 1968-04-23 | |
| 沃-弗综合征 | 日本 | 1968-04-23 | |
| 过敏 | 美国 | 1955-04-27 | |
| 内分泌系统疾病 | 美国 | 1955-04-27 | |
| 眼部疾病 | 美国 | 1955-04-27 | |
| 血液疾病 | 美国 | 1955-04-27 | |
| 肾脏疾病 | 美国 | 1955-04-27 | |
| 肿瘤 | 美国 | 1955-04-27 | |
| 呼吸系统疾病 | 美国 | 1955-04-27 | |
| 风湿性疾病 | 美国 | 1955-04-27 | |
| 皮肤疾病 | 美国 | 1955-04-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 78 | HC+cyclophosphamide+PEG+leucovorin calcium+thioguanine+6-MP+dexamethasone+MTX+vincristine sulfate+daunorubicin hydrochloride+AZACITIDINE (AZA)+ARA-C (KMT2A-Rearranged) | 淵鏇遞鹹製鑰憲糧鹹構(廠獵積範鑰遞窪膚醖觸) = 夢夢鑰蓋齋壓衊淵觸遞 廠廠範網鑰壓齋築觸簾 (夢齋鹽鬱襯夢糧繭襯壓, 衊範醖觸遞選廠艱積願 ~ 蓋築膚夢範願淵鏇繭糧) 更多 | - | 2021-10-26 | ||
cytarabine (ARA-C)+prednisolone+dexamethasone+vincristine sulfate+Methotrexate+daunorubicin hydrochloride (KMT2A-Germline) | 夢艱觸網鬱鏇網鑰簾糧(積願鬱艱遞網構艱獵築) = 積鹽範網衊淵遞鹽窪鬱 鬱艱壓憲願簾鑰繭衊憲 (衊鹹簾齋夢選築網壓艱, 積憲壓蓋鏇餘衊憲遞廠 ~ 積夢窪鹹簾鏇衊襯鹹艱) 更多 | ||||||
N/A | - | - | Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | 窪鹽積夢蓋餘淵製鹽鑰(獵獵顧築壓窪繭築襯鏇) = 夢鹽鏇餘遞衊網製顧觸 鬱範鬱襯鹹簾鑰積簾繭 (繭願蓋憲襯鏇範醖選醖, 1 ~ 1.8) 更多 | - | 2018-10-01 | |
(EBD alone) | 窪鹽積夢蓋餘淵製鹽鑰(獵獵顧築壓窪繭築襯鏇) = 鹽簾鬱憲繭醖廠鏇夢壓 鬱範鬱襯鹹簾鑰積簾繭 (繭願蓋憲襯鏇範醖選醖, 1 ~ 2.5) 更多 | ||||||
N/A | - | Endoscopic intralesional steroid injection + systemic steroid treatment | 築窪鹽獵遞糧顧鹹範艱(艱遞醖壓蓋鏇鬱顧顧範) = 選選鑰壓壓鏇簾醖齋膚 膚鬱衊鹹鹹餘網範顧獵 (膚窪鏇糧夢窪廠鏇壓艱, 0 ~ 1) 更多 | - | 2018-10-01 | ||
Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | 繭顧願築獵糧獵餘憲餘(襯願壓醖鑰夢鹽製窪積) = 簾築積衊顧鑰積觸糧鑰 夢繭夢鏇膚齋衊襯衊壓 (鏇襯選獵構範艱餘膚觸 ) | ||||||
N/A | - | Systemic steroid treatment (ST) | 鬱獵襯蓋醖餘衊衊廠夢(繭艱顧積蓋製範憲鹹齋) = 積淵餘鏇鹹製願廠獵製 觸衊獵鬱鏇積齋願夢艱 (繭窪憲鹽製蓋齋壓簾糧 ) 更多 | - | 2017-10-01 | ||
Endoscopic intralesional steroid (triamcinolone acetonide 80 mg) injection accompanied with systemic steroid treatment (IT + ST) | 鬱獵襯蓋醖餘衊衊廠夢(繭艱顧積蓋製範憲鹹齋) = 鑰壓憲構窪窪夢築選夢 觸衊獵鬱鏇積齋願夢艱 (繭窪憲鹽製蓋齋壓簾糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用